Sirolimus by OrphAI Therapeutics for Bronchiolitis Obliterans: Likelihood of Approval

Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Bronchiolitis Obliterans.

Addressing Point-of-Care Ultrasound’s Shadow IT Problem

Point-of-care ultrasound (POCUS) is taking hold across healthcare, and for good reason. By administering ultrasound technology at the point of care, whether that be the

September 5, 2023

Why health care spending keeps climbing

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in

June 17, 2024

Astrocytes found to play pivotal role in epileptic neuronal hyperactivity

Epilepsy, where patients suffer from unexpected seizures, affects roughly 1% of the population. These seizures often involve repetitive and excessive neuronal firing, with the trigger

April 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.